Clinical impact of PSMA-based 18 F –DCFBC PET/CT imaging in patients with biochemically recurrent prostate cancer after primary local therapy

Conclusions18F –DCFBC detects recurrences in 60.3% of a population of patients with biochemical recurrence, but results are dependent on PSA levels. Above a threshold PSA value of 0.78 ng/mL,18F –DCFBC was able to identify recurrence with high reliability. Positive18F –DCFBC PET imaging led clinicians to change treatment strategy in 51.2% of patients.
Source: European Journal of Nuclear Medicine and Molecular Imaging - Category: Nuclear Medicine Source Type: research